Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
13 Oct 2026

Political prioritisation as a driver of vaccine introduction: Evidence from Nigeria’s HPV rollout

Amina Abdulkarim - Solina Centre for International Development and Research (SCIDaR), Abuja, Nigeria
Political prioritisation as a driver of vaccine introduction: Evidence from Nigeria’s HPV rollout ( Amina Abdulkarim - Solina Centre for International Development and Research (SCIDaR), Abuja, Nigeria )
13 Oct 2026

Multilevel factors shaping blinatumomab delivery across diverse LMICs

Dr Caitlyn Duffy - St. Jude Children’s Research Hospital, Memphis, USA
Multilevel factors shaping blinatumomab delivery across diverse LMICs ( Dr Caitlyn Duffy - St. Jude Children’s Research Hospital, Memphis, USA )
12 Oct 2026

Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USA
Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USA )
8 Oct 2026

Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France
Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )
7 Oct 2026

Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain
Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )
6 Oct 2026

Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma

Dr Giulia Pasello - University of Padua, Padua, Italy
Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma ( Dr Giulia Pasello - University of Padua, Padua, Italy )
6 Oct 2026

Image-defined risk factors predict surgical outcomes in paediatric neuroblastic tumours

Dr Stefano Avanzini - Giannina Gaslini Institute, Genoa, Italy
Image-defined risk factors predict surgical outcomes in paediatric neuroblastic tumours ( Dr Stefano Avanzini - Giannina Gaslini Institute, Genoa, Italy )
1 Oct 2026

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )
1 Oct 2026

Transcriptome-Wide Association Study identifies genetic factors linked to subsequent cancers in childhood cancer survivors

Dr Michael Betti - St. Jude Children's Research Hospital, Memphis, USA
Transcriptome-Wide Association Study identifies genetic factors linked to subsequent cancers in childhood cancer survivors ( Dr Michael Betti - St. Jude Children's Research Hospital, Memphis, USA )
29 Sep 2026

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC ( Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
28 Sep 2026

Challenges in doing clinical research in the LATAM region

Dr Rossana Ruiz - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
Challenges in doing clinical research in the LATAM region ( Dr Rossana Ruiz - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru )
28 Sep 2026